BR0207102A - Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença - Google Patents
Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doençaInfo
- Publication number
- BR0207102A BR0207102A BR0207102-9A BR0207102A BR0207102A BR 0207102 A BR0207102 A BR 0207102A BR 0207102 A BR0207102 A BR 0207102A BR 0207102 A BR0207102 A BR 0207102A
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline form
- treatment
- pharmaceutical composition
- disease
- prevention
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000002718 pyrimidine nucleoside Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001033128 | 2001-02-09 | ||
| PCT/JP2002/000986 WO2002064609A1 (en) | 2001-02-09 | 2002-02-06 | Crystal of pyrimidine nucleoside derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0207102A true BR0207102A (pt) | 2004-01-27 |
Family
ID=18896929
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0207102-9A BR0207102A (pt) | 2001-02-09 | 2002-02-06 | Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença |
| BRPI0207102A BRPI0207102A8 (pt) | 2001-02-09 | 2002-02-06 | forma cristalina, composição farmacêutica, e, uso de uma forma cristalina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0207102A BRPI0207102A8 (pt) | 2001-02-09 | 2002-02-06 | forma cristalina, composição farmacêutica, e, uso de uma forma cristalina. |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1364959B1 (enExample) |
| JP (2) | JP3748536B2 (enExample) |
| KR (1) | KR100679904B1 (enExample) |
| CN (1) | CN100408591C (enExample) |
| AT (1) | ATE361929T1 (enExample) |
| AU (1) | AU2002230164B2 (enExample) |
| BR (2) | BR0207102A (enExample) |
| CA (1) | CA2437994C (enExample) |
| CY (1) | CY1106685T1 (enExample) |
| CZ (1) | CZ303241B6 (enExample) |
| DE (1) | DE60220024T2 (enExample) |
| DK (1) | DK1364959T3 (enExample) |
| ES (1) | ES2286237T3 (enExample) |
| HU (1) | HU229294B1 (enExample) |
| IL (2) | IL157216A0 (enExample) |
| MX (1) | MXPA03007123A (enExample) |
| NZ (1) | NZ527393A (enExample) |
| PT (1) | PT1364959E (enExample) |
| RU (1) | RU2256666C2 (enExample) |
| WO (1) | WO2002064609A1 (enExample) |
| ZA (1) | ZA200306121B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2081419B1 (en) | 1999-09-02 | 2013-08-07 | Ibiden Co., Ltd. | Printed circuit board and method of manufacturing printed circuit board |
| CN101232776B (zh) | 1999-09-02 | 2011-04-20 | 揖斐电株式会社 | 印刷布线板 |
| GB0526419D0 (en) * | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
| GB0625283D0 (en) | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| JP5066737B2 (ja) * | 2007-04-06 | 2012-11-07 | 大鵬薬品工業株式会社 | シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤 |
| US8124593B2 (en) | 2007-11-05 | 2012-02-28 | Cyclacel Limited | Methods of treatment using sapacitabine |
| GB0808357D0 (en) | 2008-05-08 | 2008-06-18 | Cyclacel Ltd | Process |
| CA2725295C (en) | 2008-06-09 | 2016-11-08 | Cyclacel Limited | Combination of sapacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine |
| US10226478B2 (en) | 2011-04-14 | 2019-03-12 | Cyclacel Limited | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
| CN108658873B (zh) * | 2012-03-15 | 2021-09-14 | 西建卡尔有限责任公司 | 表皮生长因子受体激酶抑制剂的固体形式 |
| JP7236215B2 (ja) * | 2015-03-09 | 2023-03-09 | ダブリュー・アール・グレース・アンド・カンパニー－コーン | ニコチンアミドリボシドの結晶形 |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2559917B2 (ja) * | 1990-06-15 | 1996-12-04 | 三共株式会社 | ピリミジンヌクレオシド誘導体 |
| RU2085557C1 (ru) * | 1991-09-30 | 1997-07-27 | Санкио Компани Лимитед | Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения |
-
2002
- 2002-02-04 JP JP2002026232A patent/JP3748536B2/ja not_active Expired - Lifetime
- 2002-02-06 EP EP02711347A patent/EP1364959B1/en not_active Expired - Lifetime
- 2002-02-06 MX MXPA03007123A patent/MXPA03007123A/es active IP Right Grant
- 2002-02-06 CN CNB028079337A patent/CN100408591C/zh not_active Expired - Lifetime
- 2002-02-06 RU RU2003124648/04A patent/RU2256666C2/ru active
- 2002-02-06 CZ CZ20032111A patent/CZ303241B6/cs not_active IP Right Cessation
- 2002-02-06 IL IL15721602A patent/IL157216A0/xx active IP Right Grant
- 2002-02-06 DK DK02711347T patent/DK1364959T3/da active
- 2002-02-06 AT AT02711347T patent/ATE361929T1/de active
- 2002-02-06 AU AU2002230164A patent/AU2002230164B2/en not_active Expired
- 2002-02-06 KR KR1020037010308A patent/KR100679904B1/ko not_active Expired - Lifetime
- 2002-02-06 NZ NZ527393A patent/NZ527393A/en not_active IP Right Cessation
- 2002-02-06 DE DE60220024T patent/DE60220024T2/de not_active Expired - Lifetime
- 2002-02-06 CA CA2437994A patent/CA2437994C/en not_active Expired - Lifetime
- 2002-02-06 ES ES02711347T patent/ES2286237T3/es not_active Expired - Lifetime
- 2002-02-06 BR BR0207102-9A patent/BR0207102A/pt not_active Application Discontinuation
- 2002-02-06 HU HU0303159A patent/HU229294B1/hu unknown
- 2002-02-06 BR BRPI0207102A patent/BRPI0207102A8/pt unknown
- 2002-02-06 PT PT02711347T patent/PT1364959E/pt unknown
- 2002-02-06 WO PCT/JP2002/000986 patent/WO2002064609A1/ja not_active Ceased
-
2003
- 2003-08-04 IL IL157216A patent/IL157216A/en unknown
- 2003-08-07 ZA ZA2003/06121A patent/ZA200306121B/en unknown
-
2005
- 2005-08-09 JP JP2005230800A patent/JP4356998B2/ja not_active Expired - Lifetime
-
2007
- 2007-07-02 CY CY20071100860T patent/CY1106685T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
| BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
| NO20035524D0 (no) | 4'-substituerte nukleosider | |
| BR0109703A (pt) | Derivados de piperazina | |
| TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
| DK1706403T3 (da) | Imidazo[4,5-c]pyridinforbindelser og fremgangsmåder til antiviral behandling | |
| GB0206860D0 (en) | Compounds | |
| MXPA04012965A (es) | Inhibidores virales. | |
| WO2003037860A3 (en) | Purine analogs having hsp90-inhibiting activity | |
| BR0316771A (pt) | Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica | |
| BR0309342A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
| NO20040881L (no) | Orale antidiabetes midler. | |
| WO2004014868A3 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
| BR0207102A (pt) | Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença | |
| BR0113590A (pt) | 7-oxo-piridopirimidinas | |
| ATE238981T1 (de) | Antitumorwirkstoffe | |
| DK1448562T3 (da) | Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer | |
| SE9804212D0 (sv) | Compounds | |
| MXPA04006041A (es) | Antivirales de piridoquinoxalina. | |
| SG145570A1 (en) | 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| MXPA04004621A (es) | Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn. | |
| NO20044548L (no) | Fremgangsmate for fremstilling av 6-alkaliden-penemderivater | |
| WO2003051838A3 (en) | Protein kinase inhibitors | |
| ATE266029T1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
| AU2002357740A1 (en) | Pyrazolo-pyridine derivatives as antiherpes agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |